Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Vitamin B3 cream or pills: which works better to stop skin spots?

NCT ID NCT07049068

Prevention Sponsor: Federal University of Rio Grande do Sul Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether taking nicotinamide (a form of vitamin B3) as a pill or applying it as a cream could reduce precancerous skin spots called actinic keratoses on the face. 74 adults with at least three such spots were randomly assigned to receive either oral nicotinamide plus a placebo cream, or topical nicotinamide plus a placebo pill for 6 months. The goal was to see which method worked better at preventing new spots and shrinking existing ones.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nicotinamide (a form of vitamin B3)
What this could lead to
If it works, this could point toward a simple, affordable way to prevent precancerous skin spots using vitamin B3.
What could go wrong
This is a small, early-phase study (Phase 1) with only 74 people. Results may not apply to everyone, and the effect might be small or not better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

74 people

The number who actually took part.

Started

Feb 2022

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * male individuals over 18 years of age * female individuals with tubal ligation, hysterectomy or over 45 years of age in menopause * presence of at least three palpable actinic keratoses on the face Exclusion Criteria: * individuals with an incidence of 3 or more squamous cell carcinomas in the last year * solid organ transplant recipients * carriers of the human immunodeficiency virus (HIV) * solid organs cancer * active gastric ulcer * recent history of acute myocardial infarction * hypotension * pregnancy * lactation * chronic liver disease * liver or kidney failure * xeroderma pigmentosum * albinism * epidermodysplasia verruciformis * dystrophic epidermolysis bullosa * nevoid basal cell carcinoma syndrome * individuals with a large number of confluent actinic keratosis (making it impossible to count individual lesions) * Individuals using carbamazepine * Individuals using oral retinoids * Individuals using oral supplements containing nicotinamide * Individuals who had undergone field treatments for actinic keratoses such as 5-fluorouracil in the last 4 months * individuals who were unable to understand the objectives and risks of treatment * Individuals who refused to participate or sign the consent form

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Actinic keratoses are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

actinic keratosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Actinic keratoses

Contacts and locations

Locations

  • Programa de Pós Graduação Ciencias Médicas UFRGS

    Porto Alegre, Rio Grande do Sul, 90035003, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.